Wave Eye Scouting 2020 Sip Club . . . How can we accelerate the launch and commercialization of innovative drugs?

On August 12, the Health Industry Capital Summit kicked off at the Boao Forum for Asia Hotel in Hainan, with the opening of the 2020 China Health Industry Ecological Conference.
the summit was organized by Zhongkang Information, CITIC Securities and Guosheng Securities.
held a six-day conference on the theme of "Day by Day - A New Era of Health Management for the Full Life Cycle".
As the conference's in-depth cooperative media, Sina Pharmaceuticals (micro-signal: sinayiyao) full special report, special topics, micro-blogs, WeChat synchronous pictures, for the attention of the guests of this industry event to bring a visual feast in person, we will be the first time to package the conference dry goods hard goods presented to the audience.
The following is part of KPMG China partner Yu Zilong's part of the speech: mentioned how fast innovative drugs can be listed in the market, the entire research and development process we are very concerned about input and output, the speed of accelerated market is the focus of innovative drugs, regardless of the global and China, the priority evaluation channel is the main means of innovative drugs to market, 60% are through the priority evaluation channel or listing, the priority evaluation of qualified drugs can be early market for 1-3 years, can bring a great impact on drug returns.
the current research and development hot spot around the world, immunization is the current hot spot, all the drugs in the patent period will have high-speed release and growth, including popular targets, including PD-1, CD-1 and so on.
specific products have potential in the future? What's worth paying attention to? Currently in the world's second phase of clinical drugs will become heavy drug products, of which 60% are large-molecule biopharmaceuticals, the future will continue to promote the pharmaceutical market research and development of the main force, in this 60% of biological drugs in the hot mechanism, including polypeptides, monoantibodies, antibodies and cell therapy.
Yu Zilong said that overall, we can see the future of global research and development trend objectives and fewer patients, research and development input and output pressure is increasing, like the Chinese market, now the mainstream environment of the entire market changes, long-term expired original drugs will be less and less, resulting in patent pressure in China soon occurred, to Innovation drugs left little time, because long investment in research and development, the smaller the group after the market, after the market will also face the rise of local pharmaceutical companies, as well as health care negotiations, the entire drug investment and individual drug spending is less and less, the urgent need for pharmaceutical companies to seize a limited time window to achieve commercialization success.
how to realize the success of the innovation of Chinese pharmaceutical companies? Yu Zilong pointed out that we have now overtaken the United States, the main reason is that China's innovative drugs patent application time is relatively early, a large number of patents exist in scientific research institutes and institutions, from the molecules in scientific research institutes into listed drugs have a long distance, our commercialization of the transformation is very deep, the proportion of local innovative drugs approved is increasing year by year, and the global scope, more innovative drugs through priority evaluation in China.
market promotion, the new products in the promotion model are patient-centered, seeking patient experience and overall improvement of the effect.
we should provide better treatment experiences and outcomes for patients based on medical care, outside of products, we don't care about efficacy, safety, what do we focus on bringing to patients?" For example, the improvement of quality of life and social return.
Finally market access, China's health insurance in the past is very important, now is also very important, research and development stage for medical access to provide a price evidence base, there are some medical value in market access and the role of health insurance, the whole value throughout the life cycle, more and more market access, not drilling is the negotiation of health insurance experts, value played a more and more role, the two stages of innovative drugs, In addition to health care, there are many payment models, including early bird program, discount, special drug insurance, etc., are to promote the out-of-the-money phase to improve patients' ability to pay, the health care phase, last year talked about 133 million payment model, this year's national health insurance policy just came out, this year's health care negotiations will certainly have more new models.
In addition to national health insurance, local government-led commercial insurance projects are being carried out, how to use good payment models and good resources to accelerate their own medicines, better benefit patients, while helping patients solve the problem of affordability, which is one of the key points I talked about the entrepreneurial innovation of new drugs.
note: There are deletions in the original text.